Skip to main content
SpringerLink
Log in

Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Recent studies suggest that the combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have a synergistic effect for hepatocellular carcinoma (HCC).

Aims

The aim of this meta-analysis was to compare the effectiveness of combination of RFA and TACE with that of RFA alone in patients with HCC.

Methods

Randomized controlled trials and retrospective cohort studies comparing RFA plus TACE with RFA alone for HCC were included into this meta-analysis. Study quality was rated with a standardized scale and the strength of evidence was also rated by using the grading of recommendations assessment, development, and evaluation system (GRADE system).

Results

Meta-analyses showed that the combination of RFA and TACE was obviously associated with higher survival rates (odds ratio [OR]1-year = 2.14, 95 % confidence interval [95 % CI] 1.57–2.91, P < 0.001; OR3-year = 1.98, 95 % CI 1.28–3.07, P = 0.001; OR5-year = 2.70, 95 % CI 1.42–5.14, P = 0.003). The overall quality of evidence was judged to be low by using the GRADE system.

Conclusions

The combination of TACE with RFA can improve the overall survival rate and provides better prognosis for patients with HCC, but more randomized controlled trials using large sample size are needed to provide sufficient evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–773.

    Article  CAS  PubMed  Google Scholar 

  2. Guimaraes M, Uflacker R. Locoregional therapy for hepatocellular carcinoma. Clin Liver Dis. 2011;15:395–421.

    Article  PubMed  Google Scholar 

  3. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010;52:380–388.

    Article  CAS  PubMed  Google Scholar 

  4. Kim JW, Kim JH, Won HJ, et al. Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2012;81:e189–193.

    Google Scholar 

  5. Kim JH, Won HJ, Shin YM, et al. Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011;18:1624–1629.

    Article  PubMed  Google Scholar 

  6. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30:741–749.

    Article  PubMed  Google Scholar 

  7. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg. 2011;98:1210–1224.

    Article  CAS  PubMed  Google Scholar 

  8. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.

    Article  PubMed  Google Scholar 

  9. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.

    Article  PubMed  Google Scholar 

  10. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.

    CAS  PubMed  Google Scholar 

  12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.

    Article  CAS  PubMed  Google Scholar 

  13. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129.

    Article  Google Scholar 

  14. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.

    Article  CAS  PubMed  Google Scholar 

  15. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252:905–913.

    Article  PubMed  Google Scholar 

  16. Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299:1669–1677.

    Article  CAS  PubMed  Google Scholar 

  17. Aikata H, Shirakawa H, Takaki S. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatology. 2006;44:A487.

    Article  Google Scholar 

  18. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116:5452–5460.

    Article  PubMed  Google Scholar 

  19. Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS. Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology. 2005;52:1403–1407.

    PubMed  Google Scholar 

  20. Kang CB, Xu HB, Wang SL, Rui B. Treatment of large hepatoma by TACE in combination with RFA. Chin J Hepatobiliary Surg. 2007;13:828–830.

    Google Scholar 

  21. Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life of primary hepatocellular carcinoma patients after radiofrequency ablation. Ai Zheng. 2005;24:827–833 [Article in Chinese].

    PubMed  Google Scholar 

  22. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther. 2008;25:787–794.

    Article  CAS  PubMed  Google Scholar 

  23. Xu L, Li P, Chen MS, et al. Percutaneous radiofrequency ablation combined with other minimally invasive treatments for recurrent hepatocellular carcinoma after hepatectomy. Zhonghua Wai Ke Za Zhi. 2008;46:1617–1620 [Article in Chinese].

    PubMed  Google Scholar 

  24. Shen L, Chen MH, Yan K, et al. Clinical application of a combination therapy of percutaneous radiofrequency and transcatheter arterial chemoembolization in large hepatic tumors. Zhonghua Chao Sheng Yin Xiang Xue Za Zhi. 2004;13:577–580 [Article in Chinese].

    Google Scholar 

  25. Zhang HC, Liang J. Radiofrequency ablation or transcather arterial chemoembolization for management of hepatocellular carcinoma. Zhong Guo Yi Shi Jin Xiu Za Zhi. 2007;30:67–68 [Article in Chinese].

    CAS  Google Scholar 

  26. Liang MH. Transcather arterial chemoembolization combined with radiofrequency ablation for the management of hepatocellular carcinoma. Zhong Guo Lao Nian Yi Xue Za Zhi. 2011;31:2862–2864 [Article in Chinese].

    Google Scholar 

  27. Luo ZG, Xiong K, Duan QW, Ren JM, Wang DW, Li C. Therapy of 3-dimension conformui technology guided radiofrequency ablation and trascatheter arterial chemoembolizatlon in primary hepatic carcinonm. Yunyang Yi Xue Yuan Xue Bao. 2008;27:22–25 [Article in Chinese].

    CAS  Google Scholar 

  28. Li ZR, Kang Z, Qian JS, et al. Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2007;27:1749–1751 [Article in Chinese].

    PubMed  Google Scholar 

  29. Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res. 2009;39:231–240.

    Article  CAS  PubMed  Google Scholar 

  30. Peng ZW, Chen MS, Liang HH, et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol. 2010;36:257–263.

    Article  PubMed  Google Scholar 

  31. Hu YQ. Radiofrequency ablation and transcatheter arterial chemoembolization in primary hepatic carcinoma. Contemp Med. 2011;17:232–233 [Article in Chinese].

    Google Scholar 

  32. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448–458.

    Article  PubMed  Google Scholar 

  33. Jarnagin W, Chapman WC, Curley S, et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxf). 2010;12:302–310.

    Google Scholar 

  34. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–459.

    Article  PubMed  Google Scholar 

  35. Wang N, Guan Q, Wang K, et al. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol. 2011;28:1038–1043.

    Article  CAS  PubMed  Google Scholar 

  36. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209–217.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China

    Shushan Yan & Beicheng Sun

  2. Department of Infectious Diseases, People’s Hospital of Jiangbei, Nanjing, 210048, China

    Donghua Xu

Authors
  1. Shushan Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donghua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beicheng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beicheng Sun.

Additional information

Shushan Yan and Donghua Xu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yan, S., Xu, D. & Sun, B. Combination of Radiofrequency Ablation with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis. Dig Dis Sci 57, 3026–3031 (2012). https://doi.org/10.1007/s10620-012-2212-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2212-6

Keywords

Search

Navigation